Sp717

Q&A

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions. Over the past decade, there has been tremendous progress in understanding the pathophysiology, diagnosis, and treatment of patients with these conditions. The purpose of this Clinical Symposium is to illustrate up-to-date practice guidance of common clinical scenarios in a cased-based approach by leading experts in the field.

Presenters

Speaker Image for Cynthia Levy
University of Miami
Speaker Image for David Assis
Yale University School of Medicine

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for THE PATIENT WITH PSC AND A RELEVANT STRICTURE: EVALUATION FOR EXTRA-HEPATIC CHOLANGIOCARCINOMA
THE PATIENT WITH PSC AND A RELEVANT STRICTURE: EVALUATION FOR EXTRA-HEPATIC CHOLANGIOCARCINOMA
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
Thumbnail for THE PATIENT WITH PBC AND PERSISTENTLY ELEVATED LIVER TESTS DESPITE UDCA
THE PATIENT WITH PBC AND PERSISTENTLY ELEVATED LIVER TESTS DESPITE UDCA
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
Thumbnail for TREATMENT OF THE PATIENT WITH EARLY PSC: UDCA, ORAL VANCOMYCIN, OR NEITHER
TREATMENT OF THE PATIENT WITH EARLY PSC: UDCA, ORAL VANCOMYCIN, OR NEITHER
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…